Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04514627 · ClinicalTrials.gov registry record · NA
Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19
A NA study, sponsored by Olive View-UCLA Education & Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
NCT04514627 is a NA study that has completed, run by Olive View-UCLA Education & Research Institute. The registered enrollment target is 55 participants.
The verdict
NCT04514627, a NA study, has completed, sponsored by Olive View-UCLA Education & Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
Study Summary
COVID-19 is a disease caused by the virus, SARS-CoV-2. Patients with this viral infection are at risk for developing pneumonia and acute respiratory distress syndrome (ARDS). Approximately 20% to 30% of hospitalized patients with COVID-19 and pneumonia require intensive care for respiratory support. Clinically, ARDS presents with severe hypoxemia evolving over several days to a week in combination with bilateral pulmonary infiltrates on chest X-ray. Widespread alveolar epithelial cell and pulmonary capillary endothelial injury can lead to severe impairment in gas exchange. In one report of 1,099 patients hospitalized with COVID-19, ARDS occurred in 15.6% of patients with severe pneumonia. In a smaller case series of 138 hospitalized patients, ARDS occurred in 19.6% of patients and in 61.1% of patients admitted to an intensive care unit (ICU). To date, no effective treatment has been established to treat COVID-19 or to prevent progression of ARDS. It is thought that a heightened immune response with an unbalanced release of inflammatory mediators in the airway is a major cause of morbidity and mortality associated with the disease. It is therefore reasonable to postulate that improved outcomes may be obtained in patients with a balanced immune response with adequate viral control and appropriate counter-regulatory immune responses whereas a poor outcome may be expected in patients with inadequate viral control or a heightened immune response or what is referred to as a "cytokine storm". Thus, modulating the pulmonary immune response without suppressing the immune system would be a viable strategy for patients with COVID-19. The current literature supports the role of neuromodulation, particularly vagal nerve stimulation (VNS), in modulating the immune response. Modulating the pro-inflammatory pathway through VNS has been demonstrated to decrease inflammatory mediators and improve outcomes in several animal models and in humans. Percutaneous electrical nerve field s
Interventions
- DEVICE Auricular percutaneous neurostimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2020-07-13 |
| Est. Completion | 2022-03-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04514627
The ClinicalTrials.gov registry entry for NCT04514627 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Olive View-UCLA Education & Research Institute, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Auricular percutaneous neurostimulation is the first listed.
NCT04514627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04514627 about?
NCT04514627 is a clinical study titled "Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19". COVID-19 is a disease caused by the virus, SARS-CoV-2. Patients with this viral infection are at risk for developing pneumonia and acute respiratory distress syndrome (ARDS). Approximately 20% to 30% of hospitalized patients with COVID-19 and pneumonia require intensive care for respiratory support....
What is the current status of trial NCT04514627?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2020-07-13. Estimated completion is 2022-03-22.
What interventions are being tested in trial NCT04514627?
The interventions under investigation include: Auricular percutaneous neurostimulation (DEVICE).
Who is sponsoring clinical trial NCT04514627?
This trial is sponsored by Olive View-UCLA Education & Research Institute, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.